experimental leukemia


Summary: Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.

Top Publications

  1. Gilliland D, Griffin J. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-42 pubmed
    ..Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene...
  2. Mishra S, Zhang B, Groffen J, Heisterkamp N. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl. Leukemia. 2004;18:23-8 pubmed
    ..We conclude that SCH66336, on its own, is remarkably effective in eradicating large numbers of lymphoblastic lymphoma cells and causing visible reduction in tumor size, with minimal toxicity...
  3. Gao L, Chen L, Fei X, Qiu H, Zhou H, Wang J. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model. Chin Med J (Engl). 2006;119:911-8 pubmed
    ..Since STI571 may reverse multidrug-resistance of K562/MDR cells in vitro, we studied the effect of STI571 on multidrug-resistant K562 cells in vivo...
  4. Gourzi P, Leonova T, Papavasiliou F. A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus. Immunity. 2006;24:779-86 pubmed
    ..Hence, in addition to its known function in immunoglobulin diversification, AID is active in innate defense against a transforming retrovirus...
  5. Jung Y, Kozak C. Generation of novel syncytium-inducing and host range variants of ecotropic moloney murine leukemia virus in Mus spicilegus. J Virol. 2003;77:5065-72 pubmed
  6. Kaur P, Feldhahn N, Zhang B, Trageser D, MUSCHEN M, Pertz V, et al. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer. 2007;6:67 pubmed
    ..Because Ph-positive acute lymphoblastic leukemia only responds transiently to imatinib therapy, we have used mouse models to test the efficacy of nilotinib against lymphoblastic leukemia caused by the P190 form of Bcr/Abl...
  7. James R, Edwards S, Hui K, Bassett P, Grosveld F. The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology. 1991;72:213-8 pubmed
    ..This suggests that the induction of class II antigen expression on tumour cells may provide an effective way of enhancing tumour-specific immune responses in vivo...
  8. Vasmel W, Zijlstra M, Radaszkiewicz T, Leupers C, de Goede R, Melief C. Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas. J Virol. 1988;62:3156-66 pubmed
    ..We conclude that the pleiotropic effects of MCF 1233 infection in H-2-congenic mice result from MHC class II I-A-determined T-cell response differences...
  9. Chen W, Qin H, Chesebro B, Cheever M. Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol. 1996;70:7773-82 pubmed
    ..Thus, the CTL epitope of FBL-3 is localized to the transmembrane anchor domain of the nonstructural Gag polyprotein and is shared by leukemia/lymphoma cell lines induced by Friend, Moloney, and Rauscher MuLV...

More Information

Publications108 found, 100 shown here

  1. Iwashiro M, Kondo T, Shimizu T, Yamagishi H, Takahashi K, Matsubayashi Y, et al. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol. 1993;67:4533-42 pubmed
    ..In addition, a possible third epitope was located in the N-terminal half of the gp70 sequence and differed from the first epitope in that it was not cross-reactive with the Moloney MuLV envelope protein...
  2. Anderson G, Palmer G, Rowland R, Even C, Plagemann P. Infection of central nervous system cells by ecotropic murine leukemia virus in C58 and AKR mice and in in utero-infected CE/J mice predisposes mice to paralytic infection by lactate dehydrogenase-elevating virus. J Virol. 1995;69:308-19 pubmed
  3. Ember I, Kiss I, Nowrasteh G. Different H2 haplotypes have a strong influence on oncogene action. Anticancer Res. 1999;19:1181-5 pubmed
    ..H2b expression was modest and H2d turned out to be more or less silent. The results obtained from a short term gene expression investigation shows similarity to those obtained earlier from long term leukemia inducing experiments. ..
  4. Brawand P, Lemonnier F, MacDonald H, Cerottini J, Held W. Transgenic expression of Ly49A on T cells impairs a specific antitumor response. J Immunol. 2000;165:1871-6 pubmed
  5. Hammond L, Davidson K, Lawrence R, Camden J, Von Hoff D, Weitman S, et al. Exploring the mechanisms of action of FB642 at the cellular level. J Cancer Res Clin Oncol. 2001;127:301-13 pubmed
  6. Gao X, Dinkova Kostova A, Talalay P. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc Natl Acad Sci U S A. 2001;98:15221-6 pubmed
    ..It is therefore highly likely that the multifaceted and prolonged antioxidant protection provided by sulforaphane is a general phenomenon that is mediated through induction of the Phase 2 enzyme response. ..
  7. Yu C, Lai K, Yang J, Chiang J, Lu C, Wu C, et al. Quercetin inhibited murine leukemia WEHI-3 cells in vivo and promoted immune response. Phytother Res. 2010;24:163-8 pubmed publisher
    ..Based on pathological examination, an effect of quercetin was observed in the spleen of mice previously injected with WEHI-3 cells. Apparently, quercetin affects WEHI-3 cells in vivo. ..
  8. Bernard N, Devevey L, Jacquemont C, Chretien P, Helissey P, Guillosson J, et al. A new model of pre-B acute lymphoblastic leukemia chemically induced in rats. Exp Hematol. 2005;33:1130-9 pubmed
  9. Xu X, Fei X, Chen L, Lu S, Gao L, Ni X, et al. [Establishment of a mouse model for detecting multi-drug resistant minimal residual leukemia cells expressing green fluorescent protein]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005;13:1014-7 pubmed
    ..The minimal residual leukemia cells can be observed by fluorescence microscopy in complete remission stage. ..
  10. Heuser M, Park G, Moon Y, Berg T, Xiang P, Kuchenbauer F, et al. Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia. Exp Hematol. 2010;38:174-9 pubmed publisher
    ..Our findings underscore the importance of microenvironmental signals for lineage choice in leukemia and identify signals that are important in myeloid-erythroid lineage decisions. ..
  11. Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42:530-5 pubmed publisher
    ..Our study provides genetic and functional evidence for a tumor suppressor role of PTPN2 and suggests that expression of PTPN2 may modulate response to treatment. ..
  12. Wang Y, Zhou L, Geng Y, Si L, Wang Y. [Poorly-immunogenic tumor is capable of inducing proliferation of CD4 (+) CD25 (+) regulatory T-lymphocytes in vitro]. Zhonghua Bing Li Xue Za Zhi. 2005;34:583-7 pubmed
    ..Poorly-immunogenic tumor cells can induce the proliferation of TR cells, which may play an important role in tumor evasion. ..
  13. Lee B, Sevcikova S, Kogan S. Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice. Leuk Res. 2007;31:1131-4 pubmed
    ..003) when compared to controls. Neither agent alone or in combination increased survival of control mice. These results suggest that the use of targeted therapeutics can overcome resistance to traditional chemotherapies in AML. ..
  14. Asslaber D, Pinon J, Seyfried I, Desch P, Stöcher M, Tinhofer I, et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood. 2010;115:4191-7 pubmed publisher
    ..Further, overexpression of miR-34a in primary B-CLL cells induced apoptosis. These findings suggest miR-34a as a possible therapeutic avenue and a sensitive indicator of the activity of the p53 axis in B-CLL. ..
  15. Baker J, Verneris M, Ito M, Shizuru J, Negrin R. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97:2923-31 pubmed
    ..These data indicate that CD8(+) NKT cells expanded in this fashion could be useful for preserving graft-versus-leukemia activity without causing GVHD. ..
  16. Wolff N, Ilaria R. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood. 2001;98:2808-16 pubmed
    ..This improved murine chronic-phase CML model may be a useful tool for the study of STI571 resistance, CML progression, and the anti-CML immune response. ..
  17. Snell G, Bunker H. HISTOCOMPATIBILITY GENES OF MICE. IV. THE POSITION O H-3 IN THE FIFTH LINKAGE GROUP. Transplantation. 1964;2:743-51 pubmed
  18. Zhang S, Zhang H, Wang H, Wang Q, Li W, Yu L. CD4+ T cells tumor specific response exists in L615 leukemia mice: adoptive transfer in combination with cyclophosphamide. Exp Oncol. 2004;26:156-7 pubmed
    ..We demonstrated the feasibility of separation of tumor response specific CD4+ T cells from CD4+ L615 leukemia mice. These CD4+ T cells can cure leukemia mice upon adoptive transfer in combination with cyclophosphamide pretreatment. ..
  19. Shimamoto T, Ohyashiki K, Toyama K, Takeshita K. Homeobox genes in hematopoiesis and leukemogenesis. Int J Hematol. 1998;67:339-50 pubmed
    ..In this review article, many functions of homeobox genes both at the early stem cell level as well as at the later stages of hematopoietic differentiation, and the leukemogenic effect of altered homeobox genes are discussed. ..
  20. Bowden R, Soto S, Specter S. Modulation of fas/fasL in a murine retroviral infection by AZT and methionine enkephalin. Adv Exp Med Biol. 2001;493:143-52 pubmed
  21. Prigozhina T, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol. 2002;30:89-96 pubmed
    ..Effective eradication of malignant cells can be achieved following allogeneic BMT after nonmyeloablative conditioning. ..
  22. Wu T, Lee C, Buckler White A, Kozak C. Genetic control of a mouse serum lipoprotein factor that inactivates murine leukemia viruses: evaluation of apolipoprotein F as a candidate. J Virol. 2002;76:2279-86 pubmed
  23. Le L, Kabarowski J, Wong S, Nguyen K, Gambhir S, Witte O. Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene. Cancer Cell. 2002;1:381-91 pubmed
    ..PET can be successfully applied to the temporal and spatial analysis of Bcr-Abl driven leukemic progression and should have utility for the study of other leukemias and lymphomas. ..
  24. Kraft A, Krux F, Schimmer S, Ohlen C, Greenberg P, Dittmer U. CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. Blood. 2007;109:2982-4 pubmed
    ..Thus, the transferred T cells were able to reduce chronic viral loads when combined with CpG-ODNs. This strategy provides a new approach for developing successful adoptive T-cell therapy against chronic infections. ..
  25. DiFronzo N, Holland C. Sequence-specific and/or stereospecific constraints of the U3 enhancer elements of MCF 247-W are important for pathogenicity. J Virol. 1999;73:234-41 pubmed
    ..These results are consistent with the suggestion that the virus with an interrupted enhancer changes in vivo to perform its role in the transformation of T cells...
  26. Mistry P, Plumb J, Eccles S, Watson S, Dale I, Ryder H, et al. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer. 1999;79:1672-8 pubmed
    ..In addition, the compound is well-absorbed after oral administration. These data suggest that XR9051 has the potential for reversing clinical MDR mediated by P-glycoprotien. ..
  27. Fowler D, Gress R. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma. 2000;38:221-34 pubmed
  28. Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity. 2003;18:367-79 pubmed
    ..Thus, the use of rDCs may be therapeutically useful for the treatment of acute GVHD and leukemia relapse in allogeneic BMT. ..
  29. Pollock J, Lane A, Schrimpf K, Ley T. Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica. 2005;90:1042-9 pubmed
  30. Lander J, Chesebro B, Fan H. Appearance of mink cell focus-inducing recombinants during in vivo infection by moloney murine leukemia virus (M-MuLV) or the Mo+PyF101 M-MuLV enhancer variant: implications for sites of generation and roles in leukemogenesis. J Virol. 1999;73:5671-80 pubmed
    ..On the other hand, MCFs were detected in tumors from Mo+PyF101 M-MuLV s. c.-inoculated mice even though they were largely undetectable at preleukemic times. These results support a role for MCF recombinants late in disease induction. ..
  31. Peters D, Hoover R, Gerlach M, Koh E, Zhang H, Choe K, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-12 pubmed
    ..As an oral, nontoxic compound with a mechanism of action distinct from that of ABL tyrosine kinase inhibition, FTI SCH66336 shows promise for the treatment of BCR/ABL-induced leukemia. ..
  32. Czyz M, Szuławska A. [Induced differentiation of the K562 leukemic cell line]. Postepy Hig Med Dosw (Online). 2005;59:82-97 pubmed
    ..The natural/synthetic agents inducing differentiation of human erythroleukemia K562 cells are presented. ..
  33. Fabbi M, Marimpietri D, Martini S, Brancolini C, Amoresano A, Scaloni A, et al. Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ. 1999;6:992-1001 pubmed
    ..We propose tTG cleavage as a valuable biochemical marker of caspase 3 activation during the late execution phase of apoptosis. ..
  34. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson M. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol. 2007;27:267-82 pubmed
  35. Young R, Holowka D, Baird B. A lipid raft environment enhances Lyn kinase activity by protecting the active site tyrosine from dephosphorylation. J Biol Chem. 2003;278:20746-52 pubmed
    ..In this model, cross-linking of FcepsilonRI promotes its proximity to active Lyn in a lipid raft environment. ..
  36. Cano F, Pannel R, Follows G, Rabbitts T. Preclinical modeling of cytosine arabinoside response in Mll-Enl translocator mouse leukemias. Mol Cancer Ther. 2008;7:730-5 pubmed publisher
    ..This translocator model should therefore prove useful for future drug assessments against the recurrent mixed-lineage leukemia-associated translocations. ..
  37. Clerc J, Florea B, Kraus M, Groll M, Huber R, Bachmann A, et al. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. Chembiochem. 2009;10:2638-43 pubmed publisher
    ..Our studies, therefore, propose that further development of SylA might indeed result in an improved small molecule for the treatment of leukaemia. ..
  38. Hasenkrug K. Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice. J Virol. 1999;73:6468-73 pubmed
    ..Thus, Fv-2 resistance does not independently prevent FV-induced erythroleukemia but works in concert with the immune system by limiting early infection long enough to allow virus-specific immunity time to develop and facilitate recovery...
  39. Messer R, Dittmer U, Peterson K, Hasenkrug K. Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A. 2004;101:12260-5 pubmed
    ..These results emphasize the importance of inducing both T cell responses and virus-neutralizing antibody responses for effective retroviral vaccine protection...
  40. Heuser M, Sly L, Argiropoulos B, Kuchenbauer F, Lai C, Weng A, et al. Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood. 2009;114:3983-93 pubmed publisher
    ..Our data demonstrate the functional heterogeneity of LICs and show that STAT signaling is critical for leukemia stem cell self-renewal in MN1- and HOXA9-expressing leukemias. ..
  41. Ongradi J, Specter S, Horvath A, Friedman H. Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells. Pathol Oncol Res. 1998;4:191-9 pubmed
    ..Genetic factors similar to endotoxin resistance, altered cytokine profile might determine these effects. Similar phenomena in humans might result in earlier manifestation of AIDS. ..
  42. Kanamatsu T, Watanabe R, Takase Yoden S. Cerebral metabolism in brains of rats infected with neuropathogenic murine leukemia viruses. J Vet Med Sci. 2006;68:259-65 pubmed
  43. Negishi T, Imai S, Shibuya K, Nishimura I, Shigemitsu T. Lack of promotion effects of 50 Hz magnetic fields on 7,12-dimethylbenz(a)anthracene-induced malignant lymphoma/lymphatic leukemia in mice. Bioelectromagnetics. 2008;29:29-38 pubmed
    ..These data provide no evidence to support the hypothesis that power frequency MFs is a significant risk factor for hematopoietic neoplasia. ..
  44. Hoshi M, Saito K, Hara A, Taguchi A, Ohtaki H, Tanaka R, et al. The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol. 2010;185:3305-12 pubmed publisher
  45. Chen J, Mak N, Wen J, Leung W, Chen S, Fung M, et al. A comparison of the photodynamic effects of temoporfin (mTHPC) and MC540 on leukemia cells: efficacy and apoptosis. Photochem Photobiol. 1998;68:545-54 pubmed
    ..Relative to MC540, the ability of mTHPC to trigger large-scale and thorough apoptosis in leukemia cells may help explain its potency and selectivity. ..
  46. Rulli K, Lenz J, Levy L. Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus. J Virol. 2002;76:2363-74 pubmed
    ..A model in which disrupted bone marrow hematopoiesis and thymopoiesis contribute to the development of lymphoma in the SL3-infected animal is discussed...
  47. Zhang S, Wang Q, Li W, Wang H, Zhang H, Zhu J. Different antitumor immunity roles of cytokine activated T lymphocytes from naive murine splenocytes and from dendritic cells-based vaccine primed splenocytes: implications for adoptive immunotherapy. Eksp Onkol. 2004;26:55-62 pubmed
    ..Our data demonstrate that there remain fundamentally different antitumor functions of CAT and SET which might be useful in the immunotherapy strategy choices. ..
  48. Nervi B, Ramirez P, Rettig M, Uy G, Holt M, Ritchey J, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206-14 pubmed publisher
    ..These studies provide a proof-of-principle for directing therapy to the critical tethers that promote AML-niche interactions. ..
  49. Ishii T, Udono H, Yamano T, Ohta H, Uenaka A, Ono T, et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol. 1999;162:1303-9 pubmed
    ..The implication of this evidence is also discussed in terms of the roles of hsps in MHC class I Ag processing/presentation...
  50. Louz D, van Den Broek M, Verbakel S, Vankan Y, van Lom K, Joosten M, et al. Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice. Leukemia. 2000;14:1876-84 pubmed
    ..Taken together, our results present the first evidence of Evi1 disturbing normal erythropoiesis in vivo and provides evidence for cooperative potential of Evi1 in tumor progression...
  51. Stromnes I, Dittmer U, Schumacher T, Schepers K, Messer R, Evans L, et al. Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol. 2002;76:2225-32 pubmed
    ..Eventually, all of the IFN-gamma-deficient mice failed to keep persistent virus in check and developed fatal FV-induced erythroleukemia...
  52. Turcotte K, Gauthier S, Mitsos L, Shustik C, Copeland N, Jenkins N, et al. Genetic control of myeloproliferation in BXH-2 mice. Blood. 2004;103:2343-50 pubmed
    ..Our results suggest a model in which Myls-dependent myeloproliferation in BXH-2 acts as a predisposing factor for the subsequent development of virally induced myeloid leukemia characteristic of this strain...
  53. Mayhew C, Sumpter R, Inayat M, Cibull M, Phillips J, Elford H, et al. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease. Antiviral Res. 2005;65:13-22 pubmed
    ..Moreover, the novel RR inhibitors TX and DX appear to be more effective and less myelosuppressive than HU when administered with ddI in this model...
  54. Voisin V, Barat C, Hoang T, Rassart E. Novel insights into the pathogenesis of the Graffi murine leukemia retrovirus. J Virol. 2006;80:4026-37 pubmed
    ..Furthermore, the enhancer region, different for GV-1.2 and GV-1.4, plays a pivotal role in the disease specificity: GV-1.2 induces more lymphoid leukemias, and GV-1.4 induces more nonlymphoid ones...
  55. Treshchalina E, Andronova N, Kobliakov V, Raikhlin N. [New models of experimental chemotherapy of tumors]. Vopr Onkol. 2001;47:701-5 pubmed
    ..Models of tumorous pleuritis described with respect to their response to chemotherapy, may have an application in screening and preclinical examination of newly-developed antitumor drugs...
  56. Wittich S, Scherf H, Xie C, Brosch G, Loidl P, Gerhauser C, et al. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J Med Chem. 2002;45:3296-309 pubmed
    ..In the amino acid methyl ester series, a biphenylalanine derivative was identified as a good enzyme inhibitor, which blocks proliferation in the submicromolar range and is also a potent inducer of terminal cell differentiation...
  57. Ye K, Dhiman H, Suhan J, Schultz J. Effect of pH on infectivity and morphology of ecotropic moloney murine leukemia virus. Biotechnol Prog. 2003;19:538-43 pubmed
    ..A FACS-based screening strategy for selecting high-titer retrovirus producing cell lines is also presented in this report...
  58. Hu Z, Zou P, Li A, Zhang Y, Wang L, Liu L. Study on blocking the leukemia immune escape after BMT by Fas-Fas ligand pathway. Chin Med J (Engl). 2004;117:419-24 pubmed
  59. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med. 2007;13:70-7 pubmed
    ..These findings identify NF-kappaB as one of the major mediators of Notch1-induced transformation and suggest that the NF-kappaB pathway is a potential target of future therapies of T-ALL...
  60. Krivtsov A, Wang Y, Feng Z, Armstrong S. Gene expression profiling of leukemia stem cells. Methods Mol Biol. 2009;538:231-46 pubmed publisher
    ..Here we describe methods to isolate a leukemia stem cell population, amplify RNA, and perform microarray analyses...
  61. Mayhew C, Mampuru L, Chendil D, Ahmed M, Phillips J, Greenberg R, et al. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res. 2002;56:167-81 pubmed
    ..These results suggest that due to their reduced hematopoietic toxicity and ability to inhibit disease progression in murine AIDS, TX and DX may offer effective alternatives to HU therapy in HIV-1 infection...
  62. Wolff L, Koller R, Hu X, Anver M. A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms. J Virol. 2003;77:4965-71 pubmed
    ..Interesting, MCF recombinant envelope was expressed in the lymphoid but not the myeloid neoplasms of BALB/c mice. This retrovirus has the potential for accelerating myeloid disease in genetically engineered mice...
  63. Al Bagdadi F, Seger C, Henry R, Neal Maulden G. Acute lymphoblast leukemia in sheep induced by inoculation of bovine leukemia virus: diagnostic electron microscopic morphological study. Ultrastruct Pathol. 2006;30:85-94 pubmed
    ..This study shows abundant cytoplasmic processes of hairy cell leukemia. The nuclei of the leukemia lymphoblasts showed electron-dense granules of varying sizes, which were not seen in any of the normal lymphoblasts...
  64. William B, Goodrich A, Peng C, Li S. Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia. Hematology. 2008;13:333-43 pubmed publisher
    ..We tested whether curcumin has an inhibitory effect on BCR-ABL B-cell acute lymphoblastic leukemia (B-ALL) in vitro and in vivo...
  65. Josipović P, Orsolic N. [Cytotoxicity of polyphenolic/flavonoid compounds in a leukaemia cell culture]. Arh Hig Rada Toksikol. 2008;59:299-308 pubmed publisher
    ..These results suggest a biphase effect of the tested compounds on monocyte cell lines. Cytotoxicity and growth stimulation mechanisms caused directly by flavonoids should further be investigated on the molecular level...
  66. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell. 2010;18:485-98 pubmed publisher
    ..Hence, CD4(+) T cells are required for the remodeling of the tumor microenvironment through the expression of chemokines, such as thrombospondins, in order to elicit oncogene addiction...
  67. Chervinsky D, Lam D, Zhao X, Melman M, Aplan P. Development and characterization of T cell leukemia cell lines established from SCL/LMO1 double transgenic mice. Leukemia. 2001;15:141-7 pubmed
    ..Given that SCL and LMO1 gene activation are both commonly seen in human patients with T cell acute lymphoblastic leukemia, these cell lines may be a useful in vitro model for the human disease...
  68. Tolomeo M, Grimaudo S, Milano S, La Rosa M, Ferlazzo V, Di Bella G, et al. Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines. Br J Pharmacol. 2001;133:306-14 pubmed
    ..These findings appear to support the hypothesis that CMT-8 may represent an interesting lead for the development of a new class of potent apoptosis inducer agents active in multidrug resistant and Fas-ligand resistant malignancies...
  69. Zhang J, Du Ester E, Watson R. Side-stream cigarette smoke accentuates immunomodulation during murine AIDS. Int Immunopharmacol. 2002;2:759-66 pubmed
    ..Thus, the reduction of side-stream cigarette smoke exposure is an important health issue in AIDS patients to improve the quality and quantity of their lives...
  70. Li H, Li H, Li W, Xiao L, Jiang Z, Li M, et al. [Apoptosis of cancer cells induced by influenza virus and its elementary mechanism]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003;34:409-12 pubmed
    ..To study the apotosis-inducing effects of influenza virus on cancer cells and the role of FasL...
  71. Arulanandam R, Vultur A, Raptis L. Transfection techniques affecting Stat3 activity levels. Anal Biochem. 2005;338:83-9 pubmed
    ..These results indicate that caution is required in the interpretation of results with regard to activity of Stat3 following certain commonly used transient transfection regimens...
  72. Caudell D, Harper D, Novak R, Pierce R, Slape C, Wolff L, et al. Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. Blood. 2010;115:1194-203 pubmed publisher
    ..Three mutations were identified, all of which occurred in mice with Zeb2 integrations, consistent with the hypothesis that Zeb2 and Ras pathway activation promotes B-lineage leukemic transformation in concert with CALM-AF10...
  73. Eriksson M, Leitz G, Fällman E, Axner O, Ryan J, Nakamura M, et al. Inhibitory receptors alter natural killer cell interactions with target cells yet allow simultaneous killing of susceptible targets. J Exp Med. 1999;190:1005-12 pubmed
    ..Thus, although Ly49-mediated inhibitory signals can prevent many types of effector responses, they do not globally inhibit cellular function, but rather the inhibitory signal is spatially restricted towards resistant targets...
  74. Peterson K, Iwashiro M, Hasenkrug K, Chesebro B. Major histocompatibility complex class I gene controls the generation of gamma interferon-producing CD4(+) and CD8(+) T cells important for recovery from friend retrovirus-induced leukemia. J Virol. 2000;74:5363-7 pubmed
    ..Furthermore, the influence of MHC class I genotype on the generation of both IFN-gamma-producing CD4(+) and CD8(+) T cells helps explain the major impact of the H-2D gene on recovery from FV disease...
  75. Koustova E, Sei Y, Fossom L, Wei M, Usherwood P, Keele N, et al. LP-BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor. J Clin Invest. 2001;107:737-44 pubmed
    ..These Ab's may alter neuronal signaling and contribute to the neurodegeneration observed in these mice, actions that may be curtailed by the use of AMPA-receptor antagonists...
  76. Currier N, Miller S. Echinacea purpurea and melatonin augment natural-killer cells in leukemic mice and prolong life span. J Altern Complement Med. 2001;7:241-51 pubmed
    ..Based on this evidence, our goal in the present work was to assess the role of dietary administration of this herbal extract to mice bearing leukemia, a type of tumor well known to be a target for NK cells...
  77. Aster J, Pear W. Notch signaling in leukemia. Curr Opin Hematol. 2001;8:237-44 pubmed
    ..Future studies are expected to elucidate the mechanisms by which Notch leads to transformation. Identification of the transcriptional targets of Notch signaling is likely to yield important insights...
  78. Rulli S, Muriaux D, Nagashima K, Mirro J, Oshima M, Baumann J, et al. Mutant murine leukemia virus Gag proteins lacking proline at the N-terminus of the capsid domain block infectivity in virions containing wild-type Gag. Virology. 2006;347:364-71 pubmed
    ..The results imply that CA proteins function as part of a large, highly organized structure in reverse transcription and apparently at a later step as well...
  79. Chatterjee S, Basak P, Das M, Das P, Pereira J, Dutta R, et al. Kinetic impairment of haemopoietic stem cells in experimentally induced leukemia and aplastic anemia: an inverse correlation. J Stem Cells. 2009;4:179-89 pubmed
    ..The investigations made so far revealed an interesting correlation between disease initiation and specific cytokinetic involvement of HSC in the BM microenvironment with particular reference to leukemia and aplastic anemia...
  80. Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig D, Dias S, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. 2003;17:604-11 pubmed
    ..It further underscores the efforts to identify antibodies of high affinity for enhanced antiangiogenic and antitumor activities...
  81. Slavin S, Morecki S, Weiss L, Or R. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Crit Rev Oncol Hematol. 2003;46:139-63 pubmed
  82. Somervaille T, Cleary M. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10:257-68 pubmed
  83. Sørensen K, Kunder S, Quintanilla Martinez L, Sørensen J, Schmidt J, Pedersen F. Enhancer mutations of Akv murine leukemia virus inhibit the induction of mature B-cell lymphomas and shift disease specificity towards the more differentiated plasma cell stage. Virology. 2007;362:179-91 pubmed
    ..Our results indicate that enhancer mutations weaken the ability of Akv to induce mature B-cell lymphomas prior to the plasma cell stage, whereas development of plasma cell proliferations is less dependent of viral enhancer strength...
  84. Modlich U, Schambach A, Brugman M, Wicke D, Knoess S, Li Z, et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia. 2008;22:1519-28 pubmed publisher
    ..Our study also shows that insertional mutagenesis is required for leukemia induction by IL2RG vectors, a risk to be addressed by improved vector design...
  85. Lin S, Sheen L, Chiang B, Yang J, Pan J, Chang Y, et al. Dietary effect of Antrodia Camphorate extracts on immune responses in WEHI-3 leukemia BALB/c mice. Nutr Cancer. 2010;62:593-600 pubmed publisher
    ..camphorata at 4 mg/kg in target cells at a ratio of 50:1. The percentage of macrophages with phagocyted at A. camphorata treatment increased, and these effects were in dose-dependent manners...
  86. Zeis M, Uharek L, Hartung G, Glass B, Steinmann J, Schmitz N. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice. Hematol J. 2001;2:136-44 pubmed
    ..Therefore, separation of GVL- and GVH-reactions is a long-standing goal of experimental studies dealing with allogeneic transplantation of hematopoietic stem cells...
  87. Schuch G, Machluf M, Bartsch G, Nomi M, Richard H, Atala A, et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood. 2002;100:4622-8 pubmed
    ..The use of VEGF antagonists as an antiangiogenesis approach offers a potential treatment for AML. Finally, our novel in vivo drug delivery model may be useful for testing the activities of other peptide antiangiogenic factors...
  88. Jankovicova K, Krejsek J, Kopecky O. [Multidrug resistance of leukemia cells to cytostatics--the functional fluorescent dye efflux assay evaluated by flow cytometry]. Vnitr Lek. 2001;47:25-9 pubmed
    ..The cell line K562 with transfected P-glycoprotein gene serves as a model system for the studying of the transport function with the use of the fluorescent substrates and P-glycoprotein inhibitors...
  89. Minegishi N, Suzuki N, Kawatani Y, Shimizu R, Yamamoto M. Rapid turnover of GATA-2 via ubiquitin-proteasome protein degradation pathway. Genes Cells. 2005;10:693-704 pubmed
    ..We also detected poly ubiquitinated forms of GATA-2. Taken together, these results demonstrate that GATA-2 is turned over rapidly through the ubiquitin-proteasome pathway...
  90. Honda H. [Analysis of molecular mechanisms for leukemogenesis using disease models]. Nihon Rinsho. 2007;65 Suppl 1:24-33 pubmed
  91. Li X, Chen Q, Ye Y, Fan L, Chen M, Li J, et al. [Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15:160-4 pubmed
    ..It is concluded that NKG2D and its ligands RAE-1 and H60 may play important roles in GVT response...
  92. Schlecht Louf G, Renard M, Mangeney M, Letzelter C, Richaud A, Ducos B, et al. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci U S A. 2010;107:3782-7 pubmed publisher